- Home
- PETS vs VXRT Comparison
PETS vs VXRT Comparison
Compare PETS & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- VXRT
- Stock Information
- Founded
- PETS 1996
- VXRT N/A
- Country
- PETS United States
- VXRT United States
- Employees
- PETS N/A
- VXRT N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PETS Consumer Staples
- VXRT Health Care
- Exchange
- PETS Nasdaq
- VXRT Nasdaq
- Market Cap
- PETS 105.6M
- VXRT 119.0M
- IPO Year
- PETS N/A
- VXRT N/A
- Fundamental
- Price
- PETS $4.19
- VXRT $0.41
- Analyst Decision
- PETS Sell
- VXRT Strong Buy
- Analyst Count
- PETS 2
- VXRT 2
- Target Price
- PETS $3.50
- VXRT $3.00
- AVG Volume (30 Days)
- PETS 189.8K
- VXRT 1.7M
- Earning Date
- PETS 02-10-2025
- VXRT 03-20-2025
- Dividend Yield
- PETS N/A
- VXRT N/A
- EPS Growth
- PETS N/A
- VXRT N/A
- EPS
- PETS 0.02
- VXRT N/A
- Revenue
- PETS $247,010,000.00
- VXRT $28,700,000.00
- Revenue This Year
- PETS N/A
- VXRT N/A
- Revenue Next Year
- PETS N/A
- VXRT $48.02
- P/E Ratio
- PETS $244.37
- VXRT N/A
- Revenue Growth
- PETS N/A
- VXRT 288.94
- 52 Week Low
- PETS $2.90
- VXRT $0.39
- 52 Week High
- PETS $6.85
- VXRT $1.34
- Technical
- Relative Strength Index (RSI)
- PETS 48.24
- VXRT 30.14
- Support Level
- PETS $4.02
- VXRT $0.49
- Resistance Level
- PETS $4.17
- VXRT $0.60
- Average True Range (ATR)
- PETS 0.17
- VXRT 0.05
- MACD
- PETS 0.04
- VXRT -0.01
- Stochastic Oscillator
- PETS 75.00
- VXRT 9.77
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.